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Natural immunoglobulin M (IgM) is reactive to auto-
antigens and is believed to be important for autoim-
munity. Blood pentameric IgM loaded with antigens
forms a large immune complex (IC) that contains
various elements, including apoptosis inhibitor of
macrophage (AIM). Here we demonstrate that this
IgM-AIM association contributes to autoantibody
production under obese conditions. In mice fed a
high-fat diet, natural IgM increased through B cell
TLR4 stimulation. AIM associated with IgM and pro-
tected AIM from renal excretion, increasing blood
AIM levels along with the obesity-induced IgM
augmentation. Meanwhile, the AIM association
inhibited IgM binding to the Fca/m receptor on
splenic follicular dendritic cells, thereby protecting
the IgM IC from Fca/m receptor-mediated internaliza-
tion. This supported IgM-dependent autoantigen
presentation to B cells, stimulating IgG autoantibody
production. Accordingly, in obese AIM-deficient
(AIM/) mice, the increase of multiple IgG autoanti-
bodies observed in obese wild-type mice was abro-
gated. Thus, the AIM-IgM association plays a critical
role in the obesity-associated autoimmune process.INTRODUCTION
Prominent increases in the proportion of people who suffer from
obesity in modern society have been brought about by rapid and
extreme changes in lifestyle, particularly in eating habits. ObesityCinduces the development of multiple metabolic and cardiovas-
cular diseases initially triggered by insulin resistance, which is
caused by chronic, low-grade inflammation observed in obese
adipose tissues (Hotamisligil et al., 1993; Wellen and Hotamisli-
gil, 2003; Arkan et al., 2005; Shoelson et al., 2006; Neels and
Olefsky, 2006). This subclinical state of inflammation is mainly
dependent on the innate immune system through activation of
toll-like receptors expressed on adipocytes by fatty acid, leading
to the production of inflammatory adipokines and the recruit-
ment of M1 macrophages into adipose tissues (Weisberg et al.,
2003; Xu et al., 2003; Solinas et al., 2007).
In addition to metabolic and cardiovascular diseases, many
etiological and clinical studies in humans have shown a strong
correlation between obesity and autoimmune diseases. These
are largely accompanied by increased levels of autoantibodies,
such as diabetes-associated antibodies for pancreatic b cell an-
tigens (e.g., insulin, glutamic acid decarboxylase, and protein
tyrosine phosphatase-like protein [IA2]); chronic thyroiditis-
associated thyroid peroxidase and thyroglobulin antibodies;
and infertility-associated sperm antibody (Rosenbloom, 2003;
Hersoug and Linneberg, 2007; Cambuli et al., 2010; Marzullo
et al., 2010; Badaru and Pihoker, 2012). Winer et al. (2011) also
recently demonstrated the production of pathogenic immuno-
globulin G (IgG) antibodies, including a unique profile of autoan-
tibodies in obese humans and mice. Such antibody production
was shown to be important in the acceleration of insulin
resistance. However, the elements involved in this autoimmune
process and the overall contribution of obesity to the autoanti-
body production remain unclear.
Recently, we found that macrophage-derived apoptosis
inhibitor of macrophage (AIM) plays an important role in
obesity-associated insulin resistance. AIM is a member of the
scavenger receptor cysteine-rich superfamily and was initially
identified as an apoptosis inhibitor that supports the survival ofell Reports 3, 1187–1198, April 25, 2013 ª2013 The Authors 1187
macrophages against different types of apoptosis-inducing
stimuli (Miyazaki et al., 1999). AIM is produced solely by tissue
macrophages under transcriptional regulation by nuclear recep-
tor liver X receptor/retinoid X receptor (LXR/RXR) heterodimers
(Miyazaki et al., 1999; Joseph et al., 2004; Valledor et al., 2004;
Arai et al., 2005), and serum AIM increases with the progression
of obesity in mice fed a high-fat diet (HFD) (Kurokawa et al.,
2010). We recently identified that AIM is incorporated into adipo-
cytes via CD36-mediated endocytosis and induces lipolysis
through suppression of fatty acid synthase activity, thereby
playing a role in inflammatory macrophage recruitment in obese
adipose tissue (Kurokawa et al., 2010, 2011; Miyazaki et al.,
2011; Iwamura et al., 2012; Mori et al., 2012). In agreement
with this finding, due to reduced lipolysis, obese AIM/ mice
showed a marked prevention of inflammatory macrophage infil-
tration into adipose tissue, resulting in decreased inflammation
and protection against insulin resistance and glucose intoler-
ance (Kurokawa et al., 2011; Iwamura et al., 2012).
Intriguingly, in addition to such functions, a potential associa-
tion of AIMwith natural IgM in human blood has been suggested,
although its physiological significance is entirely unknown (Tissot
et al., 2002). Due to the germline V gene segment, a large propor-
tion of natural IgM is polyreactive not only to foreign antigens but
also to phylogenetically conserved autoantigens, including
nucleic acids, heat shock proteins, carbohydrates, and phos-
pholipids, and thus is believed to be important for progression
of autoimmunity (Kantor and Herzenberg, 1993; Hardy and
Hayakawa, 1994; Boes, 2000). Moreover, natural IgM has rela-
tively low antigen-binding affinities that are compensated for
by the pentameric nature of secreted IgM. The IgM pentamer
forms an immune complex (IC) with antigen and activated com-
plement component C3, and is deposited on splenic follicular
dendritic cells (FDCs) (Pepys, 1976; Ahearn and Fearon, 1989;
Heyman, 1990; Carroll, 1998). Antigen presentation by FDC ICs
to follicular B cells is requisite for the development of long-lived
plasma cells that produce high-affinity IgGs (Allen and Cyster,
2008). Therefore, the IgM IC bound with autoantigens should
stimulate the autoantibody response that is responsible for the
progression of autoimmunity.
In this study, we attempted to determine whether AIM plays a
role in the pathogenesis of obesity-associated autoimmunity.
Our hypothesis was that binding of increased levels of AIM to
IgM under obese conditions would influence the autoantibody
production cascade.
RESULTS
AIM and IgM Pentamers Form a Complex in Blood
When we tested wild-type (WT) mouse serum for AIM (approxi-
mate molecular weight: 50 kDa; Miyazaki et al., 1999) by immu-
noblotting under nonreducing conditions, we observed the AIM
signal at a high molecular weight (>500 kDa), in a position
identical to that of pentameric IgM (Figure 1A). In addition, we
size-fractionated WT mouse serum and assessed each fraction
for AIM and IgM. As shown in Figure 1B, the fractions containing
AIM and IgM overlapped precisely, suggesting that most circu-
lating AIM is associated with IgM pentamers. Based on the
calculated mole value of blood AIM and IgM in WT mice, each1188 Cell Reports 3, 1187–1198, April 25, 2013 ª2013 The AuthorsIgM pentamer is associated with five AIMmolecules. In contrast,
AIM did not bind to IgG (Figure S1A). Recombinant AIM (rAIM)
also bound to blood IgM when tested in AIM/ mouse serum
that was incubated with rAIM (Figure 1C). Mass spectrometric
analysis of coprecipitates with the injected rAIM revealed that
AIM is a participant of the IgM IC containing many molecules,
such as complement component 1q (C1q), C3, and IgJ chain
(data not shown). The association of rAIM with different mono-
clonal IgM pentamers produced by B cell hybridoma cells was
achieved even in PBS in the absence of other participants
detectable in blood (Figure 1C). Since AIM bound to IgM regard-
less of the type of variable region, it is likely that AIM binds to
the Fc region. Consistently, a recombinant Fc protein of
secreted-type IgM associated with rAIM (Figure S1B). The
AIM-IgM interaction was also confirmed by coimmunoprecipita-
tion of endogenous AIM or injected rAIM with serum IgM
(Figure 1D).
In addition, although IgM forms a pentamer even in the
absence of the J chain (Erlandsson et al., 1998), the association
of AIM with the IgM pentamer was not obvious in serum from
mice deficient for the J chain as assessed by immunoblotting
(Figure S1C). Incubation of the serum from J-deficient mice
with rAIM did not induce complex formation between the IgM
pentamer and rAIM (Figure S1C). Note, however, that AIM did
not directly bind to the J chain (Figure S1D). Thus, it appears
that in vivo, AIM requires the J chain for its association with the
IgM pentamer, but does not need to bind directly to it. Further-
more, AIM is unlikely to attach to membrane-bound IgM, as
flow cytometry revealed that no splenic B220+ IgM+ B cells
from WT mice stained positive for AIM (data not shown). We
also assessed the binding of IgM to each of three scavenger re-
ceptor cysteine rich (SRCR) domains of AIM (Miyazaki et al.,
1999). Each of the three SRCR domains bound to IgM, but at a
markedly reduced level compared with the whole AIM protein
(Figure S1E). We previously reported that AIM does not influence
metabolic rates, including food intake and thermogenesis (Kuro-
kawa et al., 2010).We testedwhether this is also true for the AIM-
IgM complex. Lean WT mice were challenged with 100 mg of
AIM-IgM complex size-fractionated from either lean or obese
WT mice via an intravenous injection, and food intake and
body temperature were assessed. As shown in Figure S2, the
AIM-IgM complex from lean or obese mice did not change these
parameters. Similarly, introduction of the complex composed of
rAIM and a monoclonal IgM did not influence the metabolic re-
sponses (Figure S2).
Association with IgM Interferes with AIM Renal
Excretion, Resulting in Accumulation of Blood AIM
Interestingly, a strong correlation between AIM and natural IgM
levels in the blood was found in both humans and mice (Fig-
ure 2A). By contrast, this was not observed between AIM and
IgG levels (Figure 2A). Accordingly, the serum AIM level was
far lower in mice lacking blood IgM, such as Recombinase
activating gene 1 deficient (RAG1/) mice and secreted-type
IgM deficient (Dsm) mice (Boes et al., 1998), than in WT mice,
although the macrophage AIM messenger RNA (mRNA) level
was comparable in various tissues in all types ofmice (Figure 2B).
The serum AIM level was also decreased in J-chain-deficient
Figure 1. AIM and IgM Pentamer Form a Complex in Blood
(A) Immunoblotting in a nonreducing condition using AIM+/+and AIM/ sera
for AIM and IgM (n = 3 for each genotype); 1 ml of serum was used for AIM
analysis and 0.1 ml of serum was used for IgM analysis. rAIM (10 ng) and 3F3
monoclonal IgM pentamer (50 ng) proteins were used as controls.
(B) WT mouse serum (200 ml) was separated by size-exclusion chromatog-
raphy using Superdex-200 10/300 (GE Healthcare). Fast protein liquid chro-
matography was performed at 0.2 ml/min with PBS and fractioned at 1 ml
each. The fractions (10 ml each) were immunoblotted for AIM or IgM. The
protein amount curve is also presented. The peak at 66 kDa corresponds to
serum albumin. Both AIM and IgM were detected at the identical fractions at
large (>500 kDa) sizes.
(C) rAIM was incubated in AIM/ (KO) serum at 10 mg/ml or mixed with a
monoclonal IgM (3F3 or 4A2; 10 mg/ml for rAIM and 500 mg/ml for IgM) at 37C
for 16 hr in PBS, and the reactions were immunoblotted for AIM in a nonre-
ducing condition. rAIM (10 ng) was used as a control. Note that rAIM often
artificially dimerizes (indicated by arrow).
(D) Immunoprecipitation assay. Upper panel: AIM was mixed with a pen-
tameric monoclonal IgM (clone 3F3 or 1E10) at 37C for 16 hr, and then rAIM
Cmice (Figure S1F). These results indicate that association with
IgM may increase the stability of AIM protein in the blood. In
agreement with this, serum AIM levels increased rapidly when
a monoclonal mouse IgM was intravenously injected into Dsm
or RAG1/ mice (400 mg/mouse; Figure 2C).
To assess possible mechanisms that would explain how an
association with IgM stabilizes blood AIM, we intravenously in-
jected rAIM (100 mg/mouse) into mice doubly deficient for sm
and AIM (Dsm AIM/) and AIM/ mice, and kinetically tested
the serum and urine for AIM by immunoblotting and ELISA. As
depicted in Figure 2D, the observed decrease of rAIM in serum
was more prominent in Dsm AIM/ than in AIM/ mice. In par-
allel, rAIM excretion in the urine was greater in Dsm AIM/ than
in AIM/mice (Figure 2D). Thus, it appears that free AIM is
excreted in the urine, and this response is prevented through
complex formation with IgM, resulting in the accumulation of
AIM in blood to a relatively high protein concentration (10 mg/
ml). By contrast, AIM does not appear to contribute to the protein
stability of IgM, as AIM+/+ and AIM/mice showed comparable
levels of blood IgM (Figure 2E).
AIM Is Necessary for Retention of the IgM IC on
Splenic FDCs
We then assessed the in vivo localization of the AIM-IgM
complex using immunohistochemistry. It is well known that the
IgM IC is deposited on splenic FDCs through interaction be-
tween the activated complement component C3 within IC and
the FDC complement receptor (CD21/CD35), and presents anti-
gens to germinal center (GC) B cells (Pepys, 1976; Ahearn and
Fearon, 1989; Heyman, 1990; Carroll, 1998; Allen and Cyster,
2008). Therefore, we stained spleen specimens from WT mice
for AIM, IgM, and the FDC-specific marker FDC-M1. Accumula-
tion of both AIM and IgM was specifically observed in FDCs
within splenic GCs (Figure 3A). To address whether this AIM
accumulation in FDCs was IgM dependent, we injected rAIM
alone or with IgM into Dsm mice. As shown in Figure 3B, rAIM
accumulation in FDCs was only observed when rAIM was in-
jected in combination with IgM. Thus, AIM is accompanied by
the IgM IC on the surface of splenic FDCs.
Next, to test whether the AIM association might influence
the holding state of the IgM IC at FDCs, we intravenously
injected IgM alone or in association with rAIM (IgM/AIM) into
Dsm AIM/ mice and tested for the presence of IgM at the
FDC cell surface kinetically. Interestingly, when IgMwas injected
alone, no significant deposition on the surface of FDCs
(CD19CD45.2CD54+FDC-M2+) was observed, whereas the
IgM/AIM injection resulted in a profoundly increased level of
IgM on FDCs, as assessed by flow cytometry (Figure 3C). The in-
crease was still obvious even 48 hr after the injection (Figure 3C).
Parallel results were obtained when the retention of antigen at
FDCs was tested using the 2,4,6-trinitrophenyl (TNP) antigen,
which was shown to be bound to IgM (Honda et al., 2009).proteins were immunoprecipitated using an AIM antibody. The precipitates
were immunoblotted for AIM or IgM. Lower panel: Endogenous AIM was
immunoprecipitated using an AIM antibody, and the precipitates were im-
munoblotted for AIM or IgM.
See also Figures S1 and S2.
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Figure 2. Association with IgM Interferes with AIM Renal Excretion, Resulting in Accumulation of Blood AIM
(A) Correlation of serum AIM and IgM or IgG levels in humans (n = 399 for IgM and 219 for IgG) and mice (n = 20 mice). Values of R-squared and p values in
regression analysis are presented.
(B) Upper panels: Immunoblotting of serum (1 ml) from WT (AIM+/+), AIM/, RAG1/, and Dsmmice in a reducing condition for AIM and IgM. Lower panels: The
mRNA level for AIM in the spleen and liver fromRAG1/ andDsmmice was compared with that ofWTmice by qRT-PCR. No decrease in the AIMmRNA level was
observed in RAG1/ and Dsm mice.
(C) RAG1/ or Dsm mice were challenged with an intravenous injection of monoclonal IgM (clone 3F3; 400 mg). After the injection, serum AIM and IgM were
analyzed by immunoblotting at the indicated time points. Similar results were obtained in three mice for each type, and representative blots are presented.
(D) AIM/ or Dsm AIM/ mice were challenged with an intravenous injection of rAIM (100 mg) and then serum and urine were analyzed for AIM at the indicated
time points by ELISA (upper panels) and immunoblotting (lower panels; n = 3 for each type of mouse). Representative blots are presented.
(E) Serum levels of natural IgM in AIM+/+ and AIM/ mice (n = 6 each).When TNP conjugated with Ficoll was injected into AIM+/+ and
AIM/ mice, the level of TNP antigen observed on FDCs was
maintained more efficiently in AIM+/+ mice than in AIM/ mice
(Figure 3D). Consistent with this, histological results showed
that the splenic FDC area was stained for TNP 48 hr after the in-
jection in AIM+/+ mice, whereas staining levels were markedly
lower inAIM/mice (Figure 3E). Together, these results indicate
that binding of AIM to IgM is required for the retention of IgM IC
on FDCs.1190 Cell Reports 3, 1187–1198, April 25, 2013 ª2013 The AuthorsAIM Interferes with the Binding of IgM to the Fca/m
Receptor
To determine how AIM supports the retention of IgM IC at FDCs,
we decided to investigate whether the association between AIM
and the Fc region of IgM might affect the binding of IgM to
Fca/mR, the Fc-receptor for both IgM and IgA (Shibuya et al.,
2000). This investigation was based on our own observations
and previous findings that Fca/mR expression is mainly detected
on FDCs (Shibuya et al., 2000; Honda et al., 2009) and
Figure 3. Defective IgM-IC Retention at FDCs in AIM/ Mice
(A) Specimens of WT mouse spleen were stained for AIM (green), IgM (blue), and FDC-M1 (red), an FDC-specific marker. Nuclei were also stained by DAPI (light
blue). FDC areas are indicated by white arrows. Note that FDC-M1AIMIgM+ areas (yellow arrows) may correspond to the marginal zones.
(B) rAIM or IgM/AIM (250 mg of AIM) was intravenously injected into Dsmmice; 4 hr after the injection, the mice were sacrificed and their spleen specimens were
stained for AIM and FDC-M1.
(C) IgM or IgM/AIM (500 mg of IgM) was intravenously injected into Dsm AIM/mice; 12, 24, or 48 hr after the injection, the mice were sacrificed and their spleen
cells were analyzed by flow cytometry for IgM on the surface of FDCs (CD19CD45.2CD54+FDCM2+). The averages of fluorescent intensities (MFIs) for IgM in
FDCs are presented. The presented MFIs are values obtained by subtracting the background (MFI in mice without injection of IgM or IgM/AIM).
(D) TNP-Ficoll (25 mg) was intraperitoneally injected intoAIM+/+ andAIM/micewithout using adjuvant. Their spleen cells were stained for TNP aswell as the FDC
markers described above, and the TNP level on the surface of FDCs was investigated. The presented MFIs are values obtained by subtracting the background
(MFI in mice without TNP-Ficoll injection).
(E) Spleen specimens from the TNP-Ficoll-injected mice described in (D) were stained for TNP and FDC-M1 48 hr after the injection. FDC areas (FDC-M1+) are
indicated by arrows. Signals for TNP (green) were observed in AIM+/+ mice, whereas no obvious signal was detected in AIM/ mice.colocalizes with the AIM-IgM complex on the surface of FDCs
(Figure 4A), and that Fca/mR induces internalization of IgM,
thereby reducing the retention of IgM on the cell surface (Shibuya
et al., 2000). Indeed, Fca/mR/mice demonstrate advanced an-
tigen retention on FDCs when challenged with TNP antigen
(Honda et al., 2009). To address this issue, we incubated
HEK293T cells overexpressing Fca/mR with a monoclonal IgM
with or without a rAIM association, and stained them with an
IgM antibody to analyze IgM binding to the cell surface. Flow
cytometry showed that the association with AIM markedly
decreased the binding of IgM to Fca/mR (Figure 4B). Similarly,
Fca/mR-expressing HEK293T cells incubated with serum from
AIM+/+mice showed reduced surface staining for IgM comparedCwith cells incubated with AIM/ serum (Figure 4C). This effect
was also corroborated by immunoblotting. IgM was detected
in the cell lysate of Fca/mR-expressing HEK293T cells treated
with IgM in the absence of AIM, but not in that of cells treated
with IgM in the presence of AIM (Figure 4D). We next analyzed
the endocytotic incorporation of IgM through Fca/mR. Consistent
with the binding results, incorporation of fluorescein isothiocya-
nate (FITC)-labeled IgM by HEK293T cells expressing Fca/mR
was drastically decreased by the rAIM association (Figure 4E).
Thus, AIM interferes with the binding of IgM to Fca/mR and its
internalization through the receptor. Together, these results sug-
gest a model in which the IgM-dependent antigen presentation
to GC-B cells at splenic FDCs is deficient in AIM/ mice dueell Reports 3, 1187–1198, April 25, 2013 ª2013 The Authors 1191
Figure 4. Binding of IgM to Fca/mR Is Disturbed by AIM
(A) Specimens of spleen from WT mice were stained for AIM, FDC-M1, and Fca/mR.
(B) HEK293T cells transfected with an Fca/mR expression vector were treated with 3F3 monoclonal IgM (10 mg/ml), which was either not preincubated or pre-
incubated with rAIM (50 mg/ml) at 37C for 16 hr in PBS, on ice for 1 hr in PBS supplemented with 10% fetal bovine serum (FBS). The cells were then washed,
stained for IgM, and analyzed using a flow cytometer. Cells without treatment with IgM or IgM/AIM were also analyzed as a control (none). The histogram shows
the surface IgM binding in Fca/mR-expressing cells.
(C) The same cells were treated with serum from AIM+/+ (WT) or AIM/ (KO) mice (1% in PBS plus 10% FBS) on ice for 1 hr and analyzed for IgM binding as in (B).
(D) Cells treated as in (B) and (C) were lysed and analyzed for IgM by immunoblotting using an IgM antibody. Comparable results were obtained from three
independent experiments, and representative blots are shown.
(E) HEK293 cells expressing Fca/mRwere treated with IgM or IgM/AIM at 37C for 1 hr in a chamber slide glass. Cells were washed, stained for Fca/mR (red), IgM
(green), and DAPI (blue), and then investigated using a fluorescent confocal microscope. In cells treated with IgM, surface binding as well as incorporation of IgM
was clearly observed. In contrast, in cells treated with IgM/AIM, no cell-surface binding or incorporation of IgM was detected.
(F) Schema describing the role of AIM in retention of IgM IC on the surface of FDCs.
See also Figure S3.
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Figure 5. Obesity-Associated Increase in
Blood IgM
(A) Serum levels for IgM in AIM+/+and AIM/mice
fed an HFD for 0, 6, and 12 weeks, analyzed by
ELISA and immunoblotting (n = 5–6 for each
group). Statistics: *AIM+/+ versus AIM/; #versus
value in lean (0 weeks HFD) mice (AIM+/+); xversus
value in lean (0 weeks HFD) mice (AIM/). Error
bar: SEM.
(B) Serum IgM levels in WT and TLR4/ mice fed
an HFD for 0 or 6 weeks, assessed by ELISA (n = 3
for each group). Error bar: SEM.
(C) AIM+/+and AIM/ mice were challenged with
an intraperitoneal LPS injection (25 mg/mouse),
and at different time points after the injection,
serum levels for IgM were analyzed by immuno-
blotting (n = 3 for each group). Error bar: SEM.
See also Figure S4.to a rapid internalization of the IgM IC via Fca/mR (schematized
in Figure 4F).
AIM+/+ and AIM/ mice showed similar levels of both serum
complement and expression of the complement receptors
CD21/CD35 in splenic FDCs (Figures S3A and S3B). In addition,
equivalent levels of IgM binding to Fca/mR/ FDCs were
observed when cells were challenged with IgM only or IgM/
AIM (Figure S3C). Similarly, AIM accumulation at FDCs was
detectable at an equivalent level in Fca/mR/ andWTmice (Fig-
ure S3D). These results indicate that the absence of AIM does
not influence the binding of IgM ICs to CD21/CD35 on FDCs.
Thus, it is possible that the binding affinity of Fca/mR to IgM
ICsmay be higher than that of CD21/CD35, allowing the internal-
ization of the IgM IC in the absence of AIM.
Increase of Natural IgM Levels in Obese Mice via
Stimulation of TLR4 on B Cells
As expected from the correlation between AIM and natural IgM
levels in the blood (Figure 2A), the IgM level markedly increased
alongwith the AIM level (Kurokawa et al., 2010) inWTmice fed an
HFD (Figure 5A). However, a comparable increase in the IgM
level was also detected in obese AIM/ mice (Figure 5A),
indicating that the IgM increase in response to an HFD is inde-
pendent of AIM. Evidence suggests that stimulation of the cell-
surface toll-like receptor 4 (TLR4) activates splenic marginal
zone B (MZB) cells, a major producer of natural IgM (MacLennanCell Reports 3, 1187–119et al., 1982; Lopes-Carvalho and
Kearney, 2004; Pillai et al., 2005), and
subsequently induces high amounts of
polyclonal IgM production in an antigen-
independent fashion (Oliver et al., 1999;
Meyer-Bahlburg et al., 2009). As demon-
strated in Figure 5B, no significant in-
crease in blood IgM levels was observed
in TLR4/ mice fed an HFD for 6 weeks,
suggesting that the increase in natural
IgM levels in obese mice was brought
about by the stimulation of TLR4 ex-
pressed on B cells. It is possible thatincreased levels of fatty acids, which are effluxed from obese
adipocytes and/or directly supplied by an HFD, may activate B
cell TLR4 (Shi et al., 2006). Similarly, a challenge with lipopoly-
saccharide (LPS), the major ligand for TLR4, also increased
IgM levels at an equivalent level in lean AIM/ and AIM+/+
mice (Figure 5C). In ob/ob mice, a different obese animal model
caused by the absence of leptin, levels of both IgM and AIMwere
not different at 5 and 12 weeks of age, although body weights
prominently increased during the 7 weeks (Figure S4A). It is
well known that in these mice, the blood fatty acid level does
not significantly increasewith progression of obesity (Figure S4A;
also see Menahan, 1983). Thus, our result may support the
requirement of B cell TLR stimulation by fatty acids for IgM
augmentation with obesity. In parallel, deposition of AIM and
IgM at the splenic GCs was observed at a comparable level in
5- and 12-week-old ob/ob mice (Figure S4B).
Polyclonal Expansion of Autoantibodies in Obese Mice
and its Prevention in the Absence of AIM
Because of its self-reactive nature, we speculated that the
augmentation of natural IgM might stimulate IgG autoantibody
production in obese mice. To test this, we evaluated the serum
from obeseWTmice for autoantibodies using a proteomemicro-
array containing 70 autoantigens (Li et al., 2005, 2007, 2010).
Compared with lean mice, serum from mice fed an HFD for
12 weeks contained significantly increased levels of IgG8, April 25, 2013 ª2013 The Authors 1193
Figure 6. HFD-Induced Augmentation of
Autoantibodies and its Prevention in the
Absence of AIM
(A) Increase in autoantibodies in WT (AIM+/+) mice
and its prevention in AIM/ mice. Serum was
collected from lean or HFD-fed (12 weeks) AIM+/+
(white bars) and AIM/ (black bars) mice
and analyzed for autoantibodies using an auto-
antigen microarray. The antibody titers are
presented as relative values compared with lean
mice. Results for the autoantibodies that were
significantly (p < 0.05) increased in HFD-fed
AIM+/+ mice compared with lean mice are pre-
sented. The entire data are presented in Table S1
(n = 4 for each group; * indicates statistical
difference between AIM+/+ and AIM/). Error
bar: SEM.
(B) Serum levels for IgG (whole IgG and different
subclasses) in AIM+/+and AIM/mice fed an HFD
for 0, 6, and 12 weeks, analyzed by ELISA and
immunoblotting (n = 5–6 for each group). Statistics
as described in the legend for Figure 5A.
(C) Serum levels for whole IgG in AIM+/+and
AIM/ mice challenged with an intraperitoneal
LPS injection (25 mg/mouse; n = 3 for each group).
Error bar: SEM.
(D) Autoantibody production in response to
LPS analyzed using an autoantigen microarray.
Titers are presented as relative values compared
with mice without LPS challenge. Selected auto-
antibodies that were significantly (p < 0.05)
increased in AIM+/+ mice at day 11 after the LPS
challenge are presented. The entire results are
presented in Table S2; n = 3 for each group. Error
bar: SEM.
(E) Bone marrow cells were isolated from thigh
bones of HFD-fed (0 or 12 weeks) AIM+/+and
AIM/ mice, and the cell numbers depicting the
high-affinity plasma cell phenotype (intracellular
IgG+/B220/IgM/CD5/Mac-1) were evaluated
using a flow cytometer (n = 3 for each group).
Error bar: SEM.
(F) AIM+/+ and AIM/ mice were challenged with
TNP-Ficoll (25 mg) by intraperitoneal injection. On
day 28, the mice were boosted with 25 mg of TNP-
Ficoll intravenously. The mice were bled at
different time points, and the values of the TNP
IgG antibody were analyzed by ELISA using
TNP-BSA-coated plates. Serum was diluted at
1/250, and OD450 was analyzed (n = 3 for each).
Error bar: SEM.
See also Figures S5, S6, and Tables S1 and S2.autoantibodies to more than 30 variable autoantigens related to
DNA, U1RNP, histone, SSA/SSB, and the cell matrix (Figure 6A;
Table S1). In addition, the levels of all subclasses of IgG also
increased during this period (Figure 6B). Accordingly, an LPS
challenge increased the levels of whole IgG as well as some
IgG autoantibodies (Figures 6C and 6D; Table S2).
In sharp contrast, serum from AIM/mice fed an HFD for the
same period revealed markedly lower levels of IgG antibodies
against most of the autoantigens to which AIM+/+ serum
responded (Figure 6A; Table S1). Accordingly, AIM/ mice1194 Cell Reports 3, 1187–1198, April 25, 2013 ª2013 The Authorschallenged with LPS showed an abolished increase in IgG
autoantibodies (Figure 6D; Table S2). In addition, the elevation
of whole-blood IgG levels was attenuated in AIM/ mice (Fig-
ures 6B and 6C). Consistent with these findings, flow cytometric
analysis showed a decreased number of long-lived plasma cells
(intracellular IgG+/B220/IgM/CD5/Mac1; Underhill et al.,
2002), which produce high-affinity IgGs, in the bone marrow
of obese AIM/ mice compared with obese AIM+/+ mice (Fig-
ure 6E). Similarly, high-affinity IgG production against TNP
antigen, which was shown to be presented by the IgM IC
(Figures 3D and 3E; also see Honda et al., 2009), was signifi-
cantly ablated on day 35 after being boosted in AIM/ mice
(Figure 6F). Together, these results suggest that the lack of
AIM annuls the IgM-dependent maturation of high-affinity
IgG-producing plasma B cells, and thus tempers obesity-associ-
ated IgG autoantibody production.
In humans, there was a tendency for the blood AIM level to be
correlated with the body mass index (BMI) in healthy individuals
(Figure S5A). In patients harboring certain autoimmune disease,
the increase in AIM with obesity was more prominent (Fig-
ure S5B). In addition, among autoimmune patients, AIM levels
were higher in obese (BMI > 25) compared with nonobese
(BMI < 25) individuals (Figure S5B). These results suggest that
AIM is also involved in the obesity-associated autoimmune pro-
cess in humans. However, the level of AIM varied more among
individual humans than it did in mice. Because this was also
true for the IgM level, the average was similar between obese
and nonobese individuals (Figure S5B). In contrast to mice fed
an HFD, the wide variety in the eating habits of human individuals
might differently influence the blood fatty acid level, which is
critical for the augmentation of AIM and IgM (see Figure S4A).
The genetic heterogeneity present in humans may also be
involved. Further assessments in a larger number of individuals
and different types of autoimmune disease are needed to
corroborate the significance of the association of AIM with
obesity-based autoimmune diseases in humans.
Development of T Follicular Helper Cells and Ig
Recombination in GC-B Cells Were Not Affected by
a Lack of AIM
Lastly, to assess the presence of other possible mechanisms
responsible for the defective production of autoantibodies in
AIM/ mice, we investigated the development of GC-B cells
in AIM/ and AIM+/+ spleens. Prior to ensuring antigen presen-
tation by FDCs, follicular B cells undergo Ig recombination,
namely class-switch and somatic hypermutation, conducted
by activation-induced cytidine deaminase (AID; Muramatsu
et al., 2000) with the help of CXCR5+ PD-1+ GC-T follicular helper
(TFH) cells (Vogelzang et al., 2008; King et al., 2008; Vinuesa
et al., 2010) and mature to GC-B cells (Shapiro-Shelef and Cal-
ame, 2005; Cyster, 2010; McHeyzer-Williams et al., 2012; Zotos
and Tarlinton, 2012). We first confirmed that the general lympho-
cyte profiles (i.e., the number of T, follicular, andmarginal zone B
cells) were comparable in AIM/ and AIM+/+ mice under either
the lean or obese condition (Figure S6A). Flow cytometric anal-
ysis showed an equivalent number of TFH cells in the spleens
from AIM/ and AIM+/+ mice fed an HFD (Figure S6B). In addi-
tion, the AID mRNA level was also similar in obese AIM/ and
AIM+/+ spleenswhen tested by quantitative RT-PCR (qPCR) (Fig-
ure S6C). More directly, the number of IgG+B220+ B cells at GCs
was comparable in AIM/ and AIM+/+ mice fed an HFD (Fig-
ure S6D). Furthermore, we assessed whether the AIM-IgM com-
plex isolated from the serum of obese WT mice might mediate
signals through the B cell receptor (BCR) (Notley et al., 2010).
However, no significant phosphorylation of extracellular signal-
regulated kinase (ERK), an early signaling element downstream
of BCR, was not induced in CD43 splenic resting B cells by
the serum AIM-IgM complex (Figure S6E). These results suggestCthat the maturation of GC-B cells was not affected in AIM/
mice. Accordingly, the GC formation in the spleen was compara-
ble in AIM/ and AIM+/+ mice fed an HFD (Figure S6F). This
histological observation was supported by a flow cytometric
analysis revealing a similar proportion of PNA+B220+ spleen cells
(Figure S6G). Furthermore, the apoptotic state of GC-B cells in
obese AIM/ and AIM+/+mice was comparable when assessed
by TUNEL staining of spleen specimens, indicating that the
diminishment of IgG autoantibodies observed in obese AIM/
micewas not brought about by enhanced apoptosis of autoreac-
tive GC-B cells (data not shown). All of these observations further
corroborate that the deficient IgM-dependent antigen presenta-
tion in FDCs is the major mechanism responsible for the dimin-
ishment of IgG autoantibody production in obese AIM/ mice.
DISCUSSION
In this report, we present a variety of views regarding obesity-
associated autoantibody production and the roles of AIM in the
autoimmune process. First, the progression of obesity in
response to an HFD increases serum natural IgM levels via stim-
ulation of B cell TLR4. Second, the association of AIM with IgM
interferes with the binding of IgM to Fca/mR, leading to abroga-
tion of IgM internalization through Fca/mR. This response pro-
longs the presence of the IgM IC on the surface of splenic
FDCs and may advance the IgM-dependent antigen presenta-
tion to GC-B cells, thereby enhancing the development of
long-lived plasma cells that produce high-affinity IgG autoanti-
bodies. Third, the formation of an AIM-IgM pentamer complex
in the blood protects AIM from being excreted in the urine, result-
ing in its accumulation in the blood. Increased AIM levels under
the obese condition should have an advantage in augmenting
IgM-IC retention on FDCs. Fourth, in accordance with these
findings, although the increase in IgM levels in response to an
HFD is comparable in AIM+/+ and AIM/mice, the IgG increase
is diminished in AIM/ mice.
Obesity induces two distinct immunological responses: (1)
chronic inflammation through stimulation of innate immunity,
leading to insulin resistance; and (2) activation of humoral
immune responses that trigger autoantibody production. We
previously demonstrated that AIM induces lipolysis in adipo-
cytes and this response initiates the innate inflammatory
response in adipose tissue (Kurokawa et al., 2010, 2011).
Thus, this AIM function, which supports the retention of the
IgM IC on FDCs by preventing its internalization via Fca/mR,
shows that AIM is involved in both pathological pathways.
It is not immediately obvious why AIM/ mice appear to be
predominantly deficient in autoantibody production, since we
previously showed that they have normal IgG production against
specific antigens such as Keyhole Limpet Hemocyanin (KLH)-
Ficoll (Miyazaki et al., 1999). In addition, although the diminish-
ment of IgG antibody production against TNP after a boost in
AIM/micewas significant, it was still partial (Figure 6F). A plau-
sible explanation is that the presentation of autoantigens at
FDCs may be predominantly dependent on IgM, whereas KLH
or TNP may also be presented by ICs formed by low-affinity
IgGs in FDCs. The lack of AIM may not affect this process
because it does not bind to IgG. In this respect, our findingell Reports 3, 1187–1198, April 25, 2013 ª2013 The Authors 1195
that the increase in whole IgG was defective in AIM/ mice
suggests that the IgGs that were increased in obese WT mice
were selected mainly by the presentation of IgM-IC-dependent
antigens, i.e., autoantigens.
Although the augmentation of multiple autoantibodies was
observed in obese WT mice, so far, such mice have not demon-
strated any severe autoimmune disease phenotype. Many
autoimmune diseases are known to be polygenic and to harbor
multiple pathologic steps in their initiation and progression. For
instance, in systemic lupus erythematosus, the production of
IgG antibodies against nuclear antigens (ANAs) is the first step
in the development of systemic autoimmunity, although ANA
positivity is not strongly associated with any specific pathologic
consequences (Arbuckle et al., 2003; Shmerling, 2003; Fairhurst
et al., 2006). In mouse models, in addition to transition of the
Sle1 gene cluster, a collection of genes capable of converting
B6 mice to an ANA-positive phenotype, other susceptibility loci
are required to convert this autoimmune-prone phenotype into
severe disease (Morel et al., 1997, 2000; Mohan et al., 1999;
Shi et al., 2002; Subramanian et al., 2005). Therefore, whether
AIM is also associated with further pathological steps involved
in autoimmune disease progression remains an open question.
Additional experiments involving the crossbreeding of AIM/
and mouse models for various autoimmune diseases will help
further our understanding of the pathogenesis of obesity-associ-
ated autoimmune diseases.
Nevertheless, in humans, we also observed higher blood
levels of AIM in obese individuals associated with autoimmune
disease compared with those without autoimmune disease.
Although we certainly need to test a larger number of patients
and types of autoimmune diseases in order to investigate the
statistical significance of this association, our current observa-
tion implicates blood AIM as a biomarker for obesity-associated
autoimmune disease in humans. Further assessments of the
genetic variation related to endogenous AIM expression and
function, e.g., via SNP analysis and/or genome-wide sequence
studies, might help identify the pathogenesis of autoimmune dis-
eases. Interestingly, in ob/obmice, the levels of AIM and IgM did
not change with progression of obesity, supporting the require-
ment of increased levels of fatty acids in the blood to initiate
the autoimmune response triggered by the augmentation of
AIM and IgM levels. Note that to date, no observations about
the autoimmune response in ob/ob mice have been reported.
Given the wide variety of eating styles among humans, a large-
scale human cohort study might provide important information
about the correlation between blood AIM and the level and/or
profile of blood fatty acids.
Perspectives
Suppression of AIM appears to intercept two different obesity-
associated pathological immune responses, namely, chronic
inflammationbasedon innate immunity andautoantibodyproduc-
tion based on humoral immunity. Thus, AIM inhibition potentially
could be used as a therapy to prevent not only insulin resistance
and metabolic disorders but also autoimmunity under obese
conditions. Further study focusing more on human subjects will
open the door to the development of a new therapy based on
AIM suppression for obesity-associated autoimmune diseases.1196 Cell Reports 3, 1187–1198, April 25, 2013 ª2013 The AuthorsEXPERIMENTAL PROCEDURES
Mice
AIM/mice had been backcrossed to C57BL/6 (B6) for 13 generations before
they were used for experiments. Dsmmice were purchased from The Jackson
Laboratory. RAG1/ mice were kindly provided by Drs. K. Honda and
T. Taniguchi (University of Tokyo). TLR4/ mice were maintained and fed
an HFD in the Institute of Medical Science, University of Tokyo. Fca/mR/
mice were maintained at Tsukuba University. Serum from IgJ-deficient mice
was provided by Dr. T. Leanderson. All mice were maintained under specific
pathogen-free conditions. Male mice 8–12 weeks of age were fed an HFD
(HFD32, CLEA Japan).
Human Samples
The institutional committee for ethics approved our studies using human
sera, and informed consent was obtained from all subjects before the study
started.
Autoantigens Microarray
An autoantigen array bearing 70 autoantigens and eight control proteins (hIgG,
hIgM, mIgG, mIgM, anti-hIgG, anti-hIgM, anti-mIgG, and anti-mIgM) was
printed on FAST-16 slides (Whatman). Autoantigen microarrays were manu-
factured, subjected to hybridization, and scanned as previously described
(Li et al., 2005, 2007, 2010). Briefly, antigens were diluted to printing concen-
tration in printing buffer (Whatman, Sanford, ME, USA) and transferred to
384-well plates. The antigens were printed in duplicates or triplicates onto
nitrocellulose-coated 16-pad FAST slides (Whatman) by MicroGrid II 610
bio-robotics array printer (Genomic Solutions, Ann Arbor, MI, USA). After
printing, the slides were kept in a chamber with 70% humidity for 4 hr at
room temperature, and stored at 4C. Before hybridization, the slides were
kept at room temperature for 15 min, followed by incubation with the blocking
buffer (Whatman, Sanford, ME, USA) for 60 min. Then 2 ml serum was pre-
treated with 1 ml DNase-I (50 U/ml) for 30 min at room temperature in 5 ml of
buffer containing 50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2, pH 8.3. The pre-
treated serum samples were diluted 1:100 in blocking buffer, and 50 ml of
diluted serum was added to each array for 1 hr. Each array was then washed
with 100 ml of washing buffer (Whatman) three times for 5 min each, and then
Cy3-conjugated anti-human IgG and Cy5-conjugated anti-human IgM (Jack-
son ImmunoResearch, West Grove, PA, USA) at 1:1,000 dilution were applied
to each array and incubated at room temperature for 1 hr. The arrays were
washed as before, and the slides were rinsed twice with PBS and spun dry.
A Genepix 4000B scanner (Molecular Devices) with 532 nm and 635 nm
wavelengths and Genepix Pro6.0 software were used to generate the Gene
Pix Result (GPR) files. In each GRP file, the average signal intensity of the local
background was subtracted from the average signal intensity of each spot,
resulting in the background-subtracted fluorescent intensity (BSFI) of each
antigen spot. The average BSFI of duplicated spots is the mean fluorescent
intensity (MFI) for each antigen. Each antigen has at least two duplicated
spots on the array. The MFI of each antigen was normalized to the MFI of
the internal control proteins spotted on the slide (e.g., human IgG, human
IgM, mouse IgG, and mouse IgM) using the following formula: normalized
florescent intensity (NFI) = MFI of the antigen/MFI of control protein 3 1,000.
Statistical Analysis
The Mann-Whitney U test was used to calculate p values (***p < 0.001,
**p < 0.01, *p < 0.05). Error bars indicate the SEM. The correlation of serum
AIM and IgM or IgG was analyzed using regression analysis. R2 > 0.3 is
regarded as significant.
For additional details regarding themethods andmaterials used in this work,
see Extended Experimental Procedures.
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